Sept 12 (Askume) – Zenus Biopharma, which is developing immunology-based therapies, said on Thursday it had raised $225 million in a U.S. initial public offering.

The clinical-stage company, which is backed by drugmaker Bristol-Myers Squibb (BMY.N) , priced its 13.2 million share offering at $17 per share, the midpoint of its target range of $16 to $18 per share.

Categorized in:

deals, markets,

Last Update: September 13, 2024

Tagged in: